• Share
  • Email
  • Print

Philip Chui

Associate
+852.2230.3553
Fax +852.2511.9515

Mr. Chui is an associate resident in the firm’s Hong Kong office. He qualified as an attorney in New York in August 2014 and as a solicitor in Hong Kong in November 2016.

Mr. Chui is a member of the firm’s Corporate/M&A and Finance practices, and his practice focuses on U.S. law and Hong Kong law outbound acquisitions and private equity investments for corporate and financial institution clients. He has experience in private and public acquisitions, private investment in publicly-traded equities (PIPEs) and privatizations. He also has experience in structured finance transactions, including banking and finance transactions and derivatives transactions governed by the International Swaps and Derivatives Association (ISDA) Master Agreements, as well as advising on the regulatory aspects of derivatives transactions.

Professional Background

Mr. Chui joined the firm in 2014 as a trainee solicitor. Prior to joining the firm, Mr. Chui served as an intern in the enforcement division of the U.S. Securities and Exchange Commission for four months, as part of the externship program at Georgetown University Law Center.

Professional/Civic Activities

  • New York State Bar Association
  • American Bar Association
  • Advising a state-owned investment bank in the PRC on compliance with US and EU derivatives regulations, including the Dodd-Frank Act, the Volcker Rule and the European Market Infrastructure Regulation.
  • Advising a state-owned investment bank in the PRC on its equity derivatives transactions under International Swaps and Derivatives Association (ISDA) Master Agreements.
  • Advising a consortium of Taiwan shareholders in the privatization of Actions Semiconductor Inc., a Nasdaq-listed PRC provider of integrated platform solutions for IoT devices.
  • Advising the special committee of the board of directors of 21Vianet Group, Inc., a Nasdaq-listed PRC internet data center services provider, in the privatization of 21Vianet Group by a consortium led by its controlling shareholder, Kingsoft Co. Ltd. and Tsinghua Unigroup International Co. Ltd.
  • Advising Shenzhen Blue Ocean Development Fund Management Company, as general partner, and its affiliated funds in a US$ 250 million investment in the privatization of China Cord Blood Corporation, an NYSE-listed cord blood banking business , by Golden Meditech Holdings Limited, an HKSE-listed healthcare company.